- Open Access
Native extracellular matrix preserves mesenchymal stem cell “stemness” and differentiation potential under serum-free culture conditions
Stem Cell Research & Therapyvolume 6, Article number: 235 (2015)
Bone marrow-derived mesenchymal stem cells (BM-MSCs) for clinical use should not be grown in media containing fetal bovine serum (FBS), because of serum-related concerns over biosafety and batch-to-batch variability. Previously, we described the preparation and use of a cell-free native extracellular matrix (ECM) made by bone marrow cells (BM-ECM) which preserves stem cell properties and enhances proliferation. Here, we compare colony-forming ability and differentiation of MSCs cultured on BM-ECM with a commercially available matrix (CELLstart™) and tissue culture plastic (TCP) under serum-free conditions.
Primary MSCs from freshly isolated bone marrow-derived mononuclear cells or passaged MSCs (P1) were grown in serum-containing (SCM) or serum-free (SFM) media on BM-ECM, CELLstart™, or TCP substrates. Proliferation, cell composition (phenotype), colony-forming unit replication, and bone morphogenetic protein-2 (BMP-2) responsiveness were compared among cells maintained on the three substrates.
Proliferation of primary BM-MSCs was significantly higher in SCM than SFM, irrespectively of culture substrate, suggesting that the expansion of these cells requires SCM. In contrast, passaged cells cultured on BM-ECM or CELLstart™ in SFM proliferated to nearly the same extent as cells in SCM. However, morphologically, those on BM-ECM were smaller and more aligned, slender, and long.
Cells grown for 7 days on BM-ECM in SFM were 20–40 % more positive for MSC surface markers than cells cultured on CELLstart™. Cells cultured on TCP contained the smallest number of cells positive for MSC markers. MSC colony-forming ability in SFM, as measured by CFU-fibroblasts, was increased 10-, 9-, and 2-fold when P1 cells were cultured on BM-ECM, CELLstart™, and TCP, respectively. Significantly, CFU-adipocyte and -osteoblast replication of cells grown on BM-ECM was dramatically increased over those on CELLstart™ (2X) and TCP (4-7X). BM-MSCs, cultured in SFM and treated with BMP-2, retained their differentiation capacity better on BM-ECM than on either of the other two substrates.
Our findings indicate that BM-ECM provides a unique microenvironment that supports the colony-forming ability of MSCs in SFM and preserves their stem cell properties. The establishment of a robust culture system, combining native tissue-specific ECM and SFM, provides an avenue for preparing significant numbers of potent MSCs for cell-based therapies in patients.
Bone marrow-derived mesenchymal stem cells (BM-MSCs) not only replicate to produce identical daughter stem cells (self-renewal) but can differentiate into many distinct cell types, including osteoblasts, adipocytes, chondrocytes, and myocytes [1–4]. Throughout life, MSCs are continually involved in tissue regeneration and may be potentially useful as cell-based therapies for a number of diseases such as graft-versus-host disease, myocardial infarction, and diabetes (http://clinicaltrials.gov/). However, because of their relative scarcity in adult bone marrow (approximately 0.001 %) [5, 6], MSCs must be expanded in vitro to obtain sufficient numbers for basic research studies or clinical applications. Typically, the growth of MSCs requires a medium containing 10 % to 15 % fetal bovine serum (FBS). For stem cell-based therapies, alternatives to FBS have been sought since there is significant batch-to-batch variation from suppliers. More importantly, there are biosafety concerns, such as xenoimmunization and the risk of disease transmission by known or unknown pathogens (e.g., mycoplasma, viruses, and prions) [7–9].
Efforts by others have focused on developing a defined cell culture system consisting of a three-dimensional (3D) matrix, composed of purified or recombinant matrix proteins, combined with serum-free media (SFM) containing various growth factors for propagating MSCs in vitro [10–13]. Although the results using this cell culture system have shown promise when compared with culture on ordinary tissue culture plastic (TCP), these purified or recombinant matrix proteins lack critical components found in bone marrow extracellular matrix (BM-ECM). In vivo MSCs are surrounded by a rich ECM, composed of collagens, adhesion proteins, proteoglycans, and growth factors, which forms a unique microenvironment known as the “niche” [14, 15]. In this local microenvironment, MSCs not only receive signals from the ECM but actively remodel it by secreting various matrix components and proteases and depositing storage depots of growth factors. An accurate reconstruction of an authentic BM-ECM from isolated components would be difficult because of its intricate nature.
To preserve stem cell properties during culture, we developed an experimental system which mimics the in vivo microenvironment. In our approach, native ECM is systematically produced by mouse or human bone marrow cells and then decellularized [16, 17]. This native ECM is composed of at least 70 different components that include collagens (types I and III), fibronectin, small leucine-rich proteoglycans (biglycan and decorin), and basement membrane constituents (perlecan and laminin). Together, these matrix proteins play key roles in regulating cell adhesion, migration, proliferation, differentiation, and survival [18–21]. Indeed, mouse and human BM-MSCs, cultured on this cell-free BM-ECM, display enhanced attachment and proliferation while retaining their stem cell properties [16, 17]. In addition, we found that BM-MSCs maintained on BM-ECM displayed significantly increased sensitivity to growth factors such as bone morphogenetic protein-2 (BMP-2) . Furthermore, BM-MSCs expanded on BM-ECM in vitro and implanted into immunocompromised mice generated five times more bone and eight times more hematopoietic marrow compared with MSCs expanded on plastic. The ability of the ECM to promote retention of MSC properties is due, at least in part, to sequestration of endogenously produced growth factors that control MSC replication and differentiation . Recently, these findings have been independently supported by other groups [22–25].
In the present study, we hypothesize that BM-MSCs, cultured on surfaces coated with BM-ECM, will display significantly improved stem cell properties after expansion compared with cells cultured on TCP or a commercially available matrix (CELLstart™; Gibco Invitrogen, Grand Island, NY, USA), critically evaluated and tested by many research groups, and frequently used for growing human stem cells [10–13, 26], under identical SFM conditions. To test this hypothesis, we examined the capacity of BM-MSCs, after growth in SFM on the various culture substrates, for proliferation, MSC replication, differentiation, and responsiveness to BMP-2.
Preparation of human BM-MSCs
Freshly isolated human bone marrow mononuclear cells, containing BM-MSCs (primary cells) from 20- to 25-year-old donors, were purchased from Lonza Group Ltd. (Walkersville, MD, USA). Viability was more than 98 % via trypan blue exclusion. These primary cells were seeded into TCP plates (Sigma-Aldrich, St. Louis, MO, USA) at 3 × 105 cells/cm2 in “expansion medium” containing alpha-minimum essential medium (α-MEM) (Life Technologies, Grand Island, NY, USA), glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 μg/ml; Biofluids, Rockville, MD, USA), and 15 % FBS (Becton Dickinson, Franklin Lakes, NJ, USA) that had been pre-selected for its growth enhancing activity. The cells were cultured for 2–3 weeks, reaching approximately 70–80 % confluence, with half-volume media changes every 3–4 days. Non-adherent cells were removed by washing with phosphate-buffered saline (PBS). The adherent cells (passage 1; P1), identified as MSCs based on high expression (>90 %) of CD73, CD90, and CD105 and no expression of CD45, were detached by using trypsin (0.02 % for 2 minutes at 37 °C), collected by centrifugation, and resuspended in expansion media. At this point, cells were frozen for future use, used in experiments examining cell behavior, or used for the preparation of BM-ECM.
Preparation of cell-free BM-ECM
BM-ECM was prepared under aseptic conditions by using procedures developed in our lab . Briefly, BM-MSCs (P1-P3 cells) were seeded onto TCP at 6 × 103 cells/cm2 and cultured in expansion medium for 15 days with media changes every 3–4 days. During the last 8 days of culture, ascorbic acid (50 μM) (Sigma-Aldrich) was added to the media to stimulate matrix production. At harvest, the BM-ECM was extensively washed with PBS and the cells were removed by treating the matrix with 0.5 % Triton X-100 containing 20 mM NH4OH in PBS for 5 minutes at 37 °C. The resulting BM-ECM was washed with PBS an additional three times, followed by extensive washing with sterile distilled water. After the final water wash, the excess fluid was removed, and the ECM was air-dried before storing at 4 °C for up to 4 months. For use in cell culture, the ECM was re-hydrated with PBS for 1 hour at 37 °C, the PBS removed, and culture media added.
Surface characterization of cell-free BM-ECM and commercial ECM (CELLstart™)
Surface mapping of BM-ECM and CELLstart™ (Gibco Invitrogen) was performed by using a Veeco MultiMode atomic force microscope (Bruker, Santa Barbara, CA, USA) in tapping mode. Arithmetic mean roughness (Ra) and average maximum height (Rz) were obtained by measuring 15 samples of each cell culture substrate.
Proliferation of BM-MSCs maintained on TCP, cell-free BM-ECM, or commercial ECM (CELLstart™) in serum-free media
Both the proliferation of primary bone marrow cells and passaged cells (P1) grown in SFM were examined. For primary cell culture, freshly isolated human bone marrow mononuclear cells from four different 20- to 25-year-old donors (Lonza Group Ltd.) were seeded onto TCP, BM-ECM, or TCP coated with CELLstart™ (Gibco Invitrogen) prepared in accordance with the instructions of the manufacturer, in six-well plates at 5 × 105 cells/cm2. Cell cultures were performed in parallel (n = 3) in two different media: SFM, purchased from Gibco Invitrogen, was prepared in accordance with the instructions of the manufacturer, while our regular “expansion medium” (see above) was used for cultures in serum-containing media (SCM). After 3 days in culture, media were removed and replaced by fresh media to remove non-adherent cells. Once MSC colonies appeared, half-volume media changes were performed twice a week for 2 weeks. At harvest, non-adherent cells were removed by washing with PBS. Owing to differences in attachment to the different substrates, two methods of releasing the cells were required to optimize recovery and maintain cell viability (>90 % using trypan blue). Adherent cells on TCP were detached by using trypsin, while cells on CELLstart™ and BM-ECM were detached by using collagenase (type II; 400 U/ml) (Gibco Invitrogen). Irrespectively of the enzyme used, all cells were washed twice with PBS. Cell proliferation was assessed by cell counting by using a hemocytometer and trypan blue staining. Cell viability was consistently more than 90 %.
To examine the growth of passaged cells, early passage (P1) BM-MSCs (6 × 103 cells/cm2) were seeded onto TCP alone, BM-ECM, or CELLstart™ in six-well plates as described above for primary cultures. Representative cells were detached by using trypsin (cells on TCP) or collagenase (type II) (cells on ECM-coated plates), and counted after 4, 7, 10, 14, and 21 days of culture. Cell surface markers were examined by using flow cytometry (see “Flow cytometry” section below) to monitor changes in phenotype over time.
In addition, cell morphology was evaluated after 4, 7, and 10 days in culture; at harvest, culture media were removed and the cultures fixed overnight at 4 °C in 1 % paraformaldehyde. The next day the fixative was removed, 1 ml PBS added, and the wells were sealed by using Parafilm (Sigma-Aldrich). Subsequently, cells were viewed and photographed by using phase-contrast microscopy (Olympus IX73; Olympus, Tokyo, Japan). The spreading shape of cells, cultured on the various substrates for 3 days (before they reached confluence), was compared by measuring circularity (in arbitrary units) using Olympus cellSens image analysis software. Circularity (C) was calculated as a ratio of cell area (in micrometers squared) to perimeter (in micrometers) by using the formula:
Thus, the area of a cell with equal perimeter would have an idealized circular shape and a circularity of “1”. Circularity values are reported as the mean ± standard deviation (SD) of 60 randomly selected cells on a particular culture surface from three independent experiments.
Prior to seeding, baseline confirmation of BM-MSC phenotype was confirmed via fluorescence-activated cell sorting (FACS) analysis. For the present study, SSEA-4, CD73, CD90, CD105, and CD146, known markers of stem cells [27, 28], were analyzed to determine the immunophenotypic profile of the cells before and after culture on the various substrates. Single-cell suspensions (1–2 × 106) were incubated for 30 minutes at 4 °C with 100-μl aliquots (1:10 dilution) of each primary mouse antibody (SSEA-4, CD73, CD90, CD105, and CD146; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Non-specific isotype IgG was used as a negative control. Antibody-labelled cells were washed twice with staining buffer (PBS containing 5 % fetal calf serum and 0.01 % sodium azide) and then incubated for 20 minutes at 4 °C with 20 μg/ml secondary antibody (FITC-conjugated goat anti-mouse IgG; Santa Cruz Biotechnology, Inc.). Cells were then washed twice with staining buffer and either analyzed immediately or fixed by using 400 μl/tube of 1 % paraformaldehyde in PBS and stored at 4 °C until analyzed. At least 10,000 events per sample were acquired by using a Becton Dickinson FACStarplus flow cytometer to determine the percentage of positively stained cells.
Colony-forming unit replication assay
MSC colony-forming ability was determined by using a previously described replication assay . Briefly, P1 bone marrow cells were seeded at 6 × 103 cells/cm2 onto TCP, BM-ECM, or CELLstart™ and cultured in SFM for 7 days. At harvest, the cells were detached from the various surfaces, counted, and re-seeded onto plastic plates for determination of CFUs (see below). At the time of seeding onto the three different substrates, an aliquot of the P1 cells was also seeded onto plastic plates for determination of the initial numbers of CFUs as described below.
For CFU assay, cells before and after expansion on the three substrates in SFM were plated into six-well plates—100 cells per well for CFU-fibroblasts (CFU-F); 200 cells per well for CFU-adipocytes (CFU-AD) and CFU-osteoblasts (CFU-OB)—in α-MEM containing 15 % FBS. After 14 days in culture, CFU-F colonies were visualized with crystal violet staining. To assess CFU-AD colony formation, the cultures were maintained for an additional 10 days in adipogenic medium (DMEM containing 10 % FBS, 0.5 mM IBMX, 10−6 M dexamethasone, 10 μM insulin, and 200 μM indomethacin)  and then stained with Oil Red O to visualize the colonies. To assess CFU-OB colony formation, the cultures were maintained for an additional 25 days in osteoblast differentiation medium: expansion medium supplemented with 10−7 M dexamethasone (Sigma-Aldrich) and 10−4 M L-ascorbate-2-phosphate (Wako Chemicals, Richmond, VA, USA). The CFU-OB colonies were detected by von Kossa staining. The number of CFUs formed, following 7 days of expansion in SFM, was determined as previously described . MSC replication was expressed as the fold change in CFUs during the expansion: total number of CFUs obtained after cell expansion divided by the initial number of CFUs (before the expansion).
Determination of changes in osteoblast expression following treatment with BMP-2
Early passage (P1) BM-MSCs (6 × 103 cells/cm2) were seeded onto TCP, BM-ECM, or CELLstart™ in six-well plates and cultured in SFM as described above for cell proliferation. At day 7, the media were changed to α-MEM containing 2 % pre-selected FBS and the cultures continued for an additional 24 hours. The cells were then treated with recombinant human BMP-2 (60 ng/ml in PBS; Sigma-Aldrich) or vehicle for 48 hours. The dose of rhBMP-2 selected was based on preliminary studies, in which concentrations ranging from 10 to 200 ng/ml were tested and 60 ng/ml was found to provide an optimal response.
Following BMP-2 treatment, total RNA was extracted and reverse-transcribed by using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). Amplification of the cDNAs for alkaline phosphatase (ALP), bone sialoprotein (BSP), and Runx2 was performed by real-time PCR by using TaqMan Universal PCR Master Mix and Assay-on-Demand primers (Applied Biosystems). Amplification and detection were accomplished by using an ABI 7500 Real-Time PCR System (Applied Biosystems), and quantification of gene expression was obtained by subtracting the GAPDH threshold cycle (Ct) value from the Ct value of the gene of interest (ALP, BSP, or Runx2). Quantification of transcript expression was expressed as 2−ΔCt.
Statistical interpretation of data
For cell proliferation studies, each data point represented the mean ± standard deviation of three individual cultures. The data were analyzed via multi-way analysis of variance (ANOVA) following confirmation that all assumptions for ANOVA were verified. Post hoc testing was performed by using the Shapiro-Wilks normalcy test. Log values of data points were analyzed, as normalcy was not confirmed for raw data values. P values of not more than 0.05 were considered significant. Cells from four different donors (20–25 years old) were obtained from Lonza Group Ltd. and assayed separately. All results were obtained from at least three independent experiments, and each experimental treatment was performed in triplicate.
Atomic force microscopy was used to assess the surface characteristics of BM-ECM and CELLstart™. Visible differences in surface topography between the two substrates were easily discerned and quantitatively reflected in significant differences in mean roughness and maximum height (Fig. 1). BM-ECM contained fibers with regional directionality that formed “tracks” and had a mean roughness of approximately 18 nm. In contrast, CELLstart™ was more uniform and smooth and had a mean roughness of approximately 1 nm.
When freshly isolated primary human bone marrow mononuclear cells were cultured on TCP, BM-ECM, or CELLstart™, the number of cells after 2 weeks was significantly higher in SCM than SFM on all culture surfaces (Fig. 2), suggesting that expansion of primary human bone marrow cells requires SCM. Nevertheless, the primary cells maintained on BM-ECM in SCM or SFM always grew significantly faster than cells maintained on TCP or CELLstart™.
Next, we compared the proliferation of early passage (P1) human bone marrow stromal cells on the three culture surfaces in SCM or SFM (Fig. 3). When cells were cultured on either BM-ECM or CELLstart™ in SFM, proliferation followed a temporal pattern similar to that observed with SCM but was less robust. Cells cultured on BM-ECM in SFM reached confluence earlier than those on CELLstart™ (day 7 versus day 10). Except for day 10, where the number of cells on CELLstart™ was significantly higher, the number of cells in SFM cultures was similar on both matrices. In multiple repeat experiments, cells maintained for 7 days on BM-ECM in both SCM and SFM were morphologically smaller and displayed more directional alignment when compared with cells on TCP or CELLstart™ (Fig. 3, lower panels). Cell circularity, after culture for 3 days in SFM, was significantly reduced on BM-ECM versus TCP or CELLstart™ (0.06 ± 0.09, 0.24 ± 0.22, and 0.20 ± 0.23, respectively).
P1 cells that had been cultured on TCP, BM-ECM, and CELLstart™ in SFM for 4 and 7 days were analyzed for cell number and a panel of MSC surface markers (SSEA-4, CD73, CD90, CD105, and CD146). Although cells cultured for 4 days on BM-ECM showed a trend toward greater numbers of MSCs, it never attained statistical significance. In contrast, after 7 days in culture on BM-ECM, the absolute number of cells and the percent positive for MSC markers were significantly increased over cultures on CELLstart™ (Table 1 and Fig. 4b). Dot plots for cell scatter (Fig. 4a) revealed a different cell distribution after culture on CELLstart™ versus BM-ECM (small cells: approximately 30 % versus approximately 62 %; large cells: approximately 35 % versus approximately 7 %, respectively). After both 4 and 7 days, cultures on TCP contained the smallest number of cells and the lowest percent positive for MSC markers by FACS analysis.
MSC colony-forming ability was assessed by measuring the fold increase in CFU-F, CFU-AD, and CFU-OB resulting from MSC replication during 7 days of culture on TCP, BM-ECM, or CELLstart™ in SFM (Fig. 5). P1 cells were divided into aliquots for the determination of CFUs present in the initial P1 population and for expansion on TCP, BM-ECM, and CELLstart™, for the determination of replication as previously described . After 7 days of culture on the various substrates in SFM, the number of cells was obtained. The frequency of CFUs in the cells expanded on the various substrates was determined by plating the same number of cells on TCP for the colony formation assay shown in Fig. 5a. By combining the number of cells obtained from the cultures on the various substrates after 7 days and the frequency of CFUs, we determined that the number of CFU-F was increased 10-, 9-, and 2-fold when P1 cells were cultured on BM-ECM, CELLstart™, and TCP, respectively (Fig. 5b). Furthermore, differentiation capacity of the P1 cells was retained by culture on the various substrates as demonstrated by the CFU-AD and CFU-OB data (Fig. 5b). There was a significant increase in replication, reflected in the increase in CFU-AD and OB, after 7 days of culture on TCP, BM-ECM, or CELLstart™ that was above and beyond that observed for the CFU-F. Specifically, CFU-AD and -OB were increased 16- and 56-fold, respectively, after culture on BM-ECM, which was significantly higher than observed for CELLstart™ (8- and 24-fold, respectively) and TCP (4- and 8-fold, respectively).
To determine whether MSCs retain their osteoblastogenic response to exogenous BMP-2 after culture on the various substrates in SFM, P1 cells were grown on TCP, BM-ECM, and CELLstart™ for 7 days and then treated with BMP-2 (60 ng/ml) for 48 hours (Fig. 6). The expression of osteoblast markers—alkaline phosphatase (ALP), bone sialoprotein (BSP), and Runx2—was measured by TaqMan PCR. P1 cells cultured on BM-ECM and treated with BMP-2 demonstrate an increase in ALP (168-fold), BSP (24-fold), and Runx2 (1.7-fold) expression compared with untreated controls. In contrast, similarly prepared cells maintained on CELLstart™ or TCP produced a 64- or 18-fold increase in ALP expression, a 7- or 5-fold increase in BSP expression, and a 1.2- or 0.9-fold increase in Runx2 expression, respectively.
Although the composition of CELLstart™ is proprietary, we selected this culture substrate for comparison purposes because (1) CELLstart™ has been well tested for growing human MSCs [10–13, 26], (2) the same company that markets CELLstart™ also sells a compatible serum-free medium, and (3) CELLstart™, which consists of a mixture of human matrix proteins, is an ideal surface to compare with our native ECM because we believe that the native “undetached” ECM retains much of the unique architecture critical for modulating MSC behavior.
In the present study, we compared the topographical characteristics of BM-ECM and CELLstart™ and found their structural organization and surface roughness to be extremely different. One of the major advantages of BM-ECM versus culture surfaces coated with purified ECM proteins is the retention of the ECM’s unique architecture and topographical features that are responsible for cell attachment and migration . In unpublished data, we have observed that MSCs, maintained on BM-ECM, move along the fibers and display directional migration but that MSCs on TCP display random, non-directional behavior. This indicates that culture on authentic ECM minimizes contact inhibition and promotes cell proliferation.
Freshly isolated primary BM-MSCs cultured in SFM proliferated to a much smaller degree than cells grown in SCM, irrespective of the culture surface, during 14 days in culture. In addition, the number of MSCs recovered at the end of culture on BM-ECM was always greater than that after culture on TCP or CELLstart™, irrespective of the culture media (Fig. 2). This was an unexpected finding because an earlier report had demonstrated similar patterns of primary cell growth in SFM versus SCM as long as the cells were maintained on CELLstart™ . In SCM, primary BM-MSCs expanded quickly and the number of cells found after 14 days in culture was related to culture substrate (BM-ECM > CELLstart™ > TCP). Taken together, these results suggest that SFM may not provide sufficient factors to promote MSC proliferation in primary bone marrow mononuclear cell culture. It is possible that other SFMs reported in the literature are superior to the one used in this study. Here, we selected Gibco Invitrogen SFM because it is made by the same supplier as CELLstart™ and has been optimized for use with the CELLstart™ matrix. This allowed us to focus on comparing the behavior of the cells on BM-ECM versus CELLstart™ and minimize differences in various SFM from different suppliers.
The typical constituents found in SCM are numerous and include a wide range of macromolecules such as serum proteins, attachment and spreading factors, growth factors/hormones, and vitamins . However, the key components in SCM required to induce the proliferation of primary MSCs remain to be elucidated and will need to be optimized to complement the growth of MSCs during culture on BM-ECM.
Passaged (P1 and beyond) cells exhibited very similar growth trends in both SCM and SFM when cultured on CELLstart™ or BM-ECM, but not TCP. This suggests that when the cells are grown in SFM they become more dependent on their culture substrate for maintenance of proliferation, and this effect, compared with culture on TCP, is significantly enhanced by culture on 3D matrices. Although passaged cells cultured in SFM on BM-ECM showed a statistically insignificant trend toward increased proliferation compared with CELLstart™, the phenotype of the cells after culture was quite different. Morphologically, cells cultured on BM-ECM (versus CELLstart™) were smaller, spindle-shaped, directionally oriented, and densely packed and appeared more characteristic of viable stem cells. FACS analysis of cells grown on the two 3D matrices further confirmed these morphological observations. Cells cultured on BM-ECM displayed greater expression of MSC markers than cells cultured on CELLstart™, as well as TCP, after 7 days (Fig. 4). These findings indicate that the number of high-quality MSCs was increased when they were maintained on BM-ECM, as compared with TCP or CELLstart™, in a serum-free medium.
To further assess cell quality after expansion on the three different substrates in SFM, MSC colony-forming capacity was measured by using a CFU replication assay (Fig. 5). Consistent with the cell proliferation results, there was no significant difference between cells pre-cultured on BM-ECM versus CELLstart™ in terms of CFU-F replication. However, only a very small proportion of the CFU-F generated cells, pre-cultured on TCP and CELLstart™, were able to differentiate into CFU-OB. In contrast, almost 100 % of the CFU-F, pre-cultured on BM-ECM, formed CFU-OB. The results for CFU-AD were very similar to those observed with CFU-OB. These data suggest that culture on BM-ECM in SFM strongly preserves MSC differentiation capacity when compared with culture on CELLstart™.
Previously, we reported that MSCs maintained on BM-ECM in SCM displayed increased responsiveness to BMP-2 . Since growth factor responsiveness is greatly affected by the local microenvironment of the cells , we compared BMP-2 responsiveness of cells maintained on BM-ECM, CELLstart™, and TCP in SFM. Indeed, cells maintained on BM-ECM expressed remarkably higher levels of ALP and BSP in response to BMP-2 when compared with cells grown on CELLstart™ and TCP (Fig. 6). In contrast to ALP and BSP, which are later markers of osteoblast differentiation, Runx2 is a transcription factor involved in early osteoblast differentiation . The relatively low level of Runx2 expression in the present study in response to BMP-2 may be due to the fact that the cells were past the early stage of osteoblast differentiation. These data strongly support the notion that BM-ECM contains a unique architecture and protein composition that specifically modulates the presentation of growth factors to the cells as well as their activation. It remains unclear how the ECM controls cell response to growth factors. However, earlier work has shown that many proteins in the ECM bind various endogenous or exogenous growth factors and serve as a reservoir for more efficiently presenting them to their target cells [34–36].
In summary, our findings strongly indicate that native BM-ECM provides a unique microenvironment that not only improves the growth of MSCs in SFM but more importantly preserves MSC quality in terms of replication, differentiation, and BMP-2 responsiveness. The establishment of a robust culture system consisting of native tissue-specific ECM and defined SFM will allow us to prepare significant numbers of MSCs, while retaining their stem cell properties, for cell-based therapeutic applications.
Alpha-minimum essential medium
Analysis of variance
Bone marrow-derived extracellular matrix
Bone marrow-derived mesenchymal stem cell
Bone morphogenetic protein-2
Cluster of differentiation/determinants
Dulbecco’s modified Eagle’s medium
Fluorescence-activated cell sorting
Fetal bovine serum
Mesenchymal stem cell
Runt-related transcription factor-2
Stage-specific embryonic antigen-4
Tissue culture plastic
Pittenger MF, Mosca JD, McIntosh KR. Human mesenchymal stem cells: progenitor cells for cartilage, bone, fat and stroma. Curr Top Microbiol Immunol. 2000;251:3–11.
Deng J, Petersen BE, Steindler DA, Jorgensen ML, Laywell ED. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells. 2006;24:1054–64.
Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126:677–89.
Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, et al. Bone marrow as a potential source of hepatic oval cells. Science. 1999;284:1168–70.
Friedenstein AJ, Latzinik NW, Grosheva AG, Gorskaya UF. Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. Exp Hematol. 1982;10:217–27.
Wexler SA, Donaldson C, Denning-Kendall P, Rice C, Bradley B, Hows JM. Adult bone marrow is a rich source of human mesenchymal ‘stem’ cells but umbilical cord and mobilized adult blood are not. Br J Haematol. 2003;121:368–74.
Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells. 2005;23:1357–66.
Schallmoser K, Rohde E, Reinisch A, Bartmann C, Thaler D, Drexler C, et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods. 2008;14:185–96.
Tonti GA, Mannello F. From bone marrow to therapeutic applications: different behaviour and genetic/epigenetic stability during mesenchymal stem cell expansion in autologous and foetal bovine sera? Int J Dev Biol. 2008;52:1023–32.
Agata H, Watanabe N, Ishii Y, Kubo N, Ohshima S, Yamazaki M, et al. Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. Biochem Biophys Res Commun. 2009;382:353–8.
Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther. 2010;1:8.
Swamynathan P, Venugopal P, Kannan S, Thej C, Kolkundar U, Bhagwat S, et al. Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton’s jelly derived mesenchymal stem cells? A comparative study. Stem Cell Res Ther. 2014;5:88.
Swistowski A, Peng J, Han Y, Swistowska AM, Rao MS, Zeng X. Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them. PLoS One. 2009;4:e6233.
Fuchs E, Tumbar T, Guasch G. Socializing with the neighbors: stem cells and their niche. Cell. 2004;116:769–78.
Moore KA, Lemischka IR. Stem cells and their niches. Science. 2006;311:1880–5.
Chen XD, Dusevich V, Feng JQ, Manolagas SC, Jilka RL. Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J Bone Miner Res. 2007;22:1943–56.
Lai Y, Sun Y, Skinner CM, Son EL, Lu Z, Tuan RS, et al. Reconstitution of marrow-derived extracellular matrix ex vivo: a robust culture system for expanding large-scale highly functional human mesenchymal stem cells. Stem Cells Dev. 2010;19:1095–107.
Gospodarowicz DJ. Extracellular matrices and the control of cell proliferation and differentiation in vitro. Prog Clin Biol Res. 1984;145:103–28.
Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 1998;8:437–41.
Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science. 2001;294:1708–12.
Abbott A. Cell culture: biology’s new dimension. Nature. 2003;424:870–2.
Lin H, Yang G, Tan J, Tuan RS. Influence of decellularized matrix derived from human mesenchymal stem cells on their proliferation, migration and multi-lineage differentiation potential. Biomaterials. 2012;33:4480–9.
Bae SE, Bhang SH, Kim BS, Park K. Self-assembled extracellular macromolecular matrices and their different osteogenic potential with preosteoblasts and rat bone marrow mesenchymal stromal cells. Biomacromolecules. 2012;13:2811–20.
Prewitz MC, Seib FP, von Bonin M, Friedrichs J, Stiβel A, Niehage C, et al. Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments. Nat Methods. 2013;10:788–94.
Papadimitropoulos A, Scotti C, Bourgine P, Scherberich A, Martin I. Engineered decellularized matrices to instruct bone regeneration processes. Bone. 2015;70:66–72.
Hughes CS, Radan L, Betts D, Postovit LM, Lajoie GA. Proteomic analysis of extracellular matrices used in stem cell culture. Proteomics. 2011;11:3983–91.
Bara JJ, Richards RG, Alini M, Stoddart MJ. Concise review: Bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic. Stem Cells. 2014;32:1713–23.
Baker N, Boyette LB, Tuan RS. Characterization of bone marrow-derived mesenchymal stem cells in aging. Bone. 2015;70:37–47.
Sanchez-Hidalgo M, Lu Z, Tan DX, Maldonado MD, Reiter RJ, Gregerman RI. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol. 2007;292:R2208–15.
Menon NV, Chuah YJ, Phey S, Zhang Y, Wu Y, Chan V, et al. A microfluidic assay to study the combinatorial impact of substrate properties on mesenchymal stem cell migration. ACS Appl Mater Interfaces. 2015;7:17095–103.
Brunner D, Frank J, Appl H, Schoffl H, Pfaller W, Gstraunthaler G. Serum-free cell culture: the serum-free media interactive online database. ALTEX. 2010;27:53–62.
Chen XD, Fisher LW, Robey PG, Young MF. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J. 2004;18:948–58.
Ducy P. Cbfa1: a molecular switch in osteoblast biology. Dev Dyn. 2000;219:461–71.
Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell. 1991;64:867–9.
Delany AM, Canalis E. The metastasis-associated metalloproteinase stromelysin-3 is induced by transforming growth factor-beta in osteoblasts and fibroblasts. Endocrinology. 2001;142:1561–6.
Bi Y, Stuelten CH, Kilts T, Wadhwa S, Iozzo RV, Robey PG, et al. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem. 2005;280:30481–9.
This research was supported by VA Merit Review (1I01BX002145-01) and Baptist Health Foundation grants to X-DC.
X-DC is a board member of and shareholder in StemBioSys, Inc. (San Antonio, TX, USA). Other authors have no other financial or competing interests to declare.
RR, TJB, MM, JW, and QD participated in the acquisition and analysis of the data and in writing the manuscript and revising it for important intellectual content. SMJ participated in the acquisition, analysis, and interpretation of the data and in writing the manuscript and revising it for important intellectual content. DDD participated in data analysis and in drafting the manuscript and critically revising it for intellectual content. X-DC participated in the conception and design of the work, analysis and interpretation of the data, and drafting of the manuscript and takes overall responsibility for the work in its entirety. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work and ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved.
Rubie Rakian, Travis J. Block and Shannan M. Johnson contributed equally to this work.